Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Novartis Pharmaceuticals107 enrolled

Overview

The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.

This was a blinded, randomized, dose and regimen finding trial utilizing a three treatment cohort design where active TIP and TIP/Placebo cyclical (3 capsules o.d \[Cohort A\], 5 capsules o.d. \[Cohort B\] or 4 capsules b.i.d. \[Cohort C\]) versus Placebo were administered for a total of 112 days. Novartis decided to close the recruitment of new subjects into this study earlier than scheduled. Subjects who had a signed informed consent form and entered screening by 10-Sep-2018 still participated in the study. The latest possible randomization was on 08-Oct-2018. All subjects enrolled in the study (107 enrolled subjects out of 180 planned) continued as planned through to their last scheduled visit. The early recruitment halt of the study was not due to safety or lack of efficacy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

107

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions

TIPDRUG

TIP dose regimen

TIP and placeboDRUG

TIP and inhaled placebo dose regimen

PlaceboDRUG

Inhaled placebo dose regimen

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed. * Male and female patients of ≥ 18 years of age at screening (Visit 1). * Proven diagnosis of non-CF BE as documented by computed tomography or high-resolution computed tomography * At least 2 or more exacerbations treated with oral antibiotics OR 1 or more exacerbation requiring intravenous antibiotic treatment within 12 months prior to screening. * FEV1 ≥ 30% predicted at screening (Visit 1). * P. aeruginosa, must be documented in a respiratory sample at least 1 time within 12 months and also present in the expectorated sputum culture at Visit 1. Key Exclusion Criteria: * Patients with a history of cystic fibrosis. * Patients with a primary diagnosis of bronchial asthma. * Patients with a primary diagnosis of COPD associated with at least a 20 pack year smoking history. * Any significant medical condition that is either recently diagnosed or was not stable during the last 3 months, other than pulmonary exacerbations, and that in the opinion of the investigator makes participation in the trial against the patients' best interests. * Clinically significant (in the opinion of the investigator) hearing loss that interferes with patients' daily activities (such as normal conversations) or chronic tinnitus. Patients with a past history of clinically significant hearing loss in the opinion of the investigator may be eligible only if their hearing threshold at screening audiometry is 25dB or lower at frequencies 0.5-4 kHz. The use of a hearing device is reflective of a clinically significant hearing loss; hence patients using hearing aids at screening are not eligible. * Patients with active pulmonary tuberculosis. * Patients currently receiving treatment for nontuberculous mycobacterial (NTM) pulmonary disease. * Patients who are regularly receiving inhaled anti-pseudomonal antibiotic (during the study inhaled anti-pseudomonal antibiotics are not allowed other than the study drug).

Locations (34)

Outcomes

Primary Outcomes

Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)

Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes presented.

Time frame: Baseline (Visit 101/Day 1), Visit 102 (Day 8), Visit 103 (Day 29)

Secondary Outcomes

Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)

Time frame: Baseline (Visit 101/Day 1), Visit 104 (Day 57), Visit 105 (Day 85), Visit 106 (Day 113), End of Treatment (EOT), Visit 201 (Day 141), Visit 202 (Day 169)

Time to First Onset of Pulmonary Exacerbation by Exacerbation Category

The time to first onset of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. Participants were censored at the time of completion of study or early discontinuation if they did not have a pulmonary exacerbation during the study period.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Brussels, Belgium

Novartis Investigative Site

Leuven, Belgium

Novartis Investigative Site

Nice, Cedex1, France

Novartis Investigative Site

Montpellier, Herault, France

Novartis Investigative Site

Grenoble, France

Novartis Investigative Site

Toulouse, France

Novartis Investigative Site

Essen, North Rhine-Westphalia, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Frankfurt, Germany

Novartis Investigative Site

Hanover, Germany

...and 24 more locations

Duration of Pulmonary Exacerbation by Exacerbation Category

The duration of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Exposure Adjusted Rate of Pulmonary Exacerbations (PE) Over the Entire Study Period

The exposure adjusted rate of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. The Exposure adjusted rate = (Number of pulmonary exacerbations reported during the study period) / (sum of study duration in days for all participants/ 365.25). Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Percentage of Participants With at Least One Pulmonary Exacerbation by Exacerbation Category

Pulmonary exacerbations are defined as events requiring antibiotic therapy AND for which at least 3 of the following 6 symptoms, signs, or findings were present outside of normal variation: 1. Increased sputum volume, or change in viscosity/consistency or purulence for more than 24 hours; 2. Increased shortness of breath at rest or on exercise for more than 24 hours; 3. Increased cough for more than 24 hours; 4. Fever of ≥38° Celsius within the last 24 hours; 5. Increased malaise/fatigue/lethargy for more than 24 hours; 6. A reduction in forced expiratory volume in the first second of expiration (FEV1) or forced vital capacity (FVC) of least 10% from screening. Participants were categorized as: a) Overall, b) Category 1: treated with oral antibiotics only and c) Category 2: treated with parenteral Antibiotics and/or requiring hospitalization. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Percentage of Participants Who Permanently Discontinued Study Drug Due to Pulmonary Exacerbation

The percentage of participants who permanently discontinued study drug due to pulmonary exacerbation compared to placebo was analyzed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Time to Permanent Study Drug Discontinuation Due to Pulmonary Exacerbation

The time to permanent study drug discontinuation due to Pulmonary exacerbation. Participants were censored at the time of last contact if they did not permanently discontinue study drug due to pulmonary exacerbation requiring during the study period. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Time to First Use (Overall, Oral, and Parenteral) of Anti-pseudomonal Antibiotics Usage

The time to first use of anti-pseudomonal antibiotics administered compared to placebo was analyzed. Participants were censored at the time of last contact if they did not have anti-pseudomonal antibiotics over the entire study period.

Time frame: From Baseline (Visit 101/Day 1) up to approximately Day 173

Percentage of Participants Requiring Anti-pseudomonal Antibiotics

The percentage of participants requiring anti-pseudomonal antibiotics compared to placebo was analyzed. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Duration of Anti-pseudomonal Antibiotics Usage

The total number of days of new anti-pseudomonal antibiotic use compared to placebo was analyzed. Only descriptive analysis

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Percentage of Participants Requiring Hospitalization Due to Serious Respiratory-related Adverse Events

The percentage of participants requiring hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Duration of Hospitalization Due to Serious Respiratory-related Adverse Events

The duration of hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Number of Hospitalization Due to Serious Respiratory-related Adverse Events

The number of hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Respiratory related adverse events were identified using the AEs captured under system organ class 'Respiratory, thoracic and mediastinal disorders' and 'Infections and infestations'.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Time to First Hospitalization Due to Serious Respiratory-related Adverse Events

Time to first hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Participants were censored at the time of last contact if they did not have a hospitalization due to serious respiratory-related adverse events over the entire study period.

Time frame: Baseline (Visit 101/Day 1) to Visit 202 (Day 169)

Serum Tobramycin Concentration

The serum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in serum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Serum specimens for PK tobramycin concentration were assessed at Visit 101 (Day 1/start of treatment) 0 to 1 and 1 to 2 hours post-dose and Visit 102 (Day 8) 0 to 1 and 1 to 2 hours post-dose. Prior to protocol amendment #2, PK samples were assessed on Visits 103 (Day 29) rather than Visit 102. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1), Visit 102 (Day 8) and Visits 103 (Day 29): 0-1 hours and 1-2 hours post-dose.

Sputum Tobramycin Concentration

The sputum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in sputum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Only descriptive analysis performed.

Time frame: Baseline (Visit 101/Day 1): 0-1 hours and 1-2 hours post-dose; Visit 102 (Day 8):0-2 hours and 5-6 hours post-dose; Visits 103 (Day 29): 5 to 6 hours post-dose, Visit 104 (Day 57) and Visit 105 (Day 85): 3-4 hours post-dose.

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Physical Functioning

The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Role Functioning

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Vitality

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Emotional Functioning

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Social Functioning

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Treatment Burden

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Health Perceptions

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)

Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Respiratory Symptoms

Time frame: Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)